» Articles » PMID: 30271432

Confocal Microscopy Predicts the Risk of Recurrence and Malignant Transformation of Mucocutaneous Neurofibromas in NF-1: An Observational Study

Overview
Publisher Wiley
Specialty Dermatology
Date 2018 Oct 2
PMID 30271432
Authors
Affiliations
Soon will be listed here.
Abstract

From 2005 to 2010, 20 consecutive patients with fully manifested neurofibromatosis type 1 (NF1) underwent elective neurofibroma resection at our institution (Departments of Plastic Surgery and of Odontostomatology). Specimens were photographed under optical microscope and confocal laser scanning microscopy (CLSM) with ultra-high accuracy of detail, including depth of field. Patients were followed up for a minimum of 4 years and up to a maximum of 12 years, postsurgery. While all nonrecurring lesions showed intense fluorescence, six of the seven lesions with absence of fluorescence under CLSM recurred at a mean of 5.5 years after surgical excision. Among the re-excised lesions, 3 were diagnosed as malignant at the subsequent removal. Despite the limitation of a small cohort, CLSM appears to be a simple and low-cost technique to differentiate forms of neurofibromas with low and high risk of recurrence and malignant degeneration.

References
1.
Philpott C, Tovell H, Frayling I, Cooper D, Upadhyaya M . The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017; 11(1):13. PMC: 5480124. DOI: 10.1186/s40246-017-0109-3. View

2.
Cannon A, Chen M, Li P, Boyd K, Theos A, Redden D . Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis. 2018; 13(1):31. PMC: 5803843. DOI: 10.1186/s13023-018-0772-z. View

3.
Liao C, Pradhan S, Chen Z, Patel A, Booker R, Le L . The role of nerve microenvironment for neurofibroma development. Oncotarget. 2016; 7(38):61500-61508. PMC: 5308667. DOI: 10.18632/oncotarget.11133. View

4.
Guida M, Cramarossa A, Fistola E, Porcelli M, Giudice G, Lubello K . High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. J Transl Med. 2010; 8:115. PMC: 2992498. DOI: 10.1186/1479-5876-8-115. View

5.
Mahalingam M . NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma. Adv Anat Pathol. 2016; 24(1):1-14. DOI: 10.1097/PAP.0000000000000131. View